RetractedTrialPloS one2022

RETRACTED: Improvement of non-invasive tests of liver steatosis and fibrosis as indicators for non-alcoholic fatty liver disease in type 2 diabetes mellitus patients with elevated cardiovascular risk profile using the PPAR-α/γ agonist aleglitazar.

Esmée J Grobbee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.